Authors

• Irzal Hadžibegović — University Hospital Dubrava, Zagreb, Croatia
• Ivana Jurin — University Hospital Dubrava, Zagreb, Croatia
• Ivan Skorić — University of Zagreb, Zagreb, Croatia
• Miroslav Raguž — University Hospital Dubrava, Zagreb, Croatia
• Ilko Vuksanović — University Hospital Dubrava, Zagreb, Croatia
• Mario Udovičić — University Hospital Dubrava, Zagreb, Croatia
• Ante Lisičić — University Hospital Dubrava, Zagreb, Croatia
• Tomislav Šipić — University Hospital Dubrava, Zagreb, Croatia
• Nikola Pavlović — University Hospital Dubrava, Zagreb, Croatia
• Marin Pavlov — University Hospital Dubrava, Zagreb, Croatia
• Aleksandar Blivajs — University Hospital Dubrava, Zagreb, Croatia
• Tomislava Bodrožić Džakić Poljak — University Hospital Dubrava, Zagreb, Croatia
• Anđela Jurišić — University Hospital Dubrava, Zagreb, Croatia
• Dominik Buljan — University Hospital Dubrava, Zagreb, Croatia
• Šime Manola — University Hospital Dubrava, Zagreb, Croatia

Abstract

**Introduction**: Guidelines recommend scrutinized lipid management after percutaneous coronary intervention (PCI) in acute coronary syndromes (ACS), with proposed values of LDL cholesterol (LDL-C) below 1.4 mmol/L. (1) We investigated real-world results of lipid management at least 6 months after PCI in ACS in regard to clinical outcomes. **Patients and Methods**: We analyzed in-hospital and follow-up data of patients who underwent PCI in ACS during a 1-year period from 2019 to 2020, were discharged in stable condition with adequate statin dose and other optimal therapy and survived at least 6 months with available control laboratory parameters. **Results**: Out of 421 patients discharged with proposed maximum statin therapy after PCI in ACS, only 24% had LDL-C levels 2.6 mmol/L (HR 1.68; 95% CI 1.15-2.47; significantly higher compared to patients with LDL-C <2.6 mmol/L at follow-up). **Conclusion**: Among patients who have an indication for reimbursed advanced (parenteral) lipid therapy early after PCI in ACS, there is a substantial number of patients who need statin dose adjustment and better compliance to statins. Additional education of patients after PCI in ACS to optimize compliance for statin therapy is highly needed, as well as early monitoring of lipid management to optimize outcomes.

Keywords

acute coronary syndrome, percutaneous coronary intervention, dyslipidemia

DOI

Literature

1. Wang Y, Yan BP, Nichol MB, Tomlinson B, Lee VWY. Real-world study of low-density lipoprotein cholesterol levels and cardiovascular outcomes in Chinese: A retrospective cohort study in post-percutaneous coronary intervention acute coronary syndrome patients. Int J Cardiol. 2017 December 15;249:18–24. https://doi.org/10.1016/j.ijcard.2017.07.016